274 articles published
Merck's Pneumococcal Vaccine Wins U.S. Approval for High-Risk Children and Teenagers
Merck received U.S. FDA approval to expand the use of its pneumococcal vaccine to include certain high-risk children and adolescents,...
Read Full Analysis
Pfizer CFO Dave Denton to Step Down in August
Pfizer announced that Chief Financial Officer Dave Denton will step down from his position in August, marking a significant leadership change...
Read Full Analysis
Trump Administration Asks Appeals Court to Allow Kennedy's Vaccine Panel Appointments
The Trump administration asked a federal appeals court to allow Health Secretary Robert F. Kennedy Jr. to move forward with appointments he...
Read Full Analysis
U.S. Health Department Proposes Testosterone Therapy Label Updates
The U.S. Department of Health and Human Services announced proposed updates to safety labeling requirements for testosterone replacement...
Read Full Analysis
CDC Activates $107 Million in Emergency Funding for Ebola Response
The Centers for Disease Control and Prevention (CDC) activated approximately $107 million in emergency funding to strengthen the United...
Read Full Analysis
FDA Advisers Vote in Favor of Moderna's Flu Vaccine
An independent panel of FDA advisers voted in favor of recommending Moderna's experimental flu vaccine, bringing the company one step closer...
Read Full Analysis
FTC Requires Aurobindo Pharma to Divest Four Drug Products to Complete Acquisition
The U.S. Federal Trade Commission (FTC) announced that Aurobindo Pharma must divest four pharmaceutical products before it can complete its...
Read Full Analysis
Biogen to Acquire RayThera in Deal Worth Up to $1 Billion
Biogen announced an agreement to acquire private biotechnology company RayThera in a deal worth up to $1 billion, continuing the company's...
Read Full Analysis
Jazz Pharmaceuticals and AbCellera Sign Antibody Discovery Deal Worth Up to $876 Million
Jazz Pharmaceuticals and biotechnology company AbCellera announced a new partnership focused on discovering and developing antibody-based...
Read Full Analysis
Progesterone Supplies Tighten as Demand for Menopause Treatments Continues to Grow
Supplies of progesterone, a hormone commonly used in menopause treatment, are becoming increasingly tight in the United States as demand...
Read Full Analysis
Robots Improve Drug Testing by Detecting Hidden Cancer Cells Researchers Often Miss
Researchers reported that robotic laboratory systems are helping improve the accuracy of drug testing by identifying small numbers of...
Read Full Analysis
uniQure Receives FDA Guidance to Pursue Approval for Huntington’s Gene Therapy
uniQure announced on June 17, 2026, that it has reached a significant regulatory milestone for its experimental gene therapy, AMT-130, for...
Read Full Analysis
U.S. Health Department Announces More Than $700 Million to Combat Mental Health and Addiction
The U.S. Department of Health and Human Services (HHS) announced more than $700 million in funding to support mental health services,...
Read Full Analysis
FDA Staff Says Data May Support Moderna's Flu Vaccine for Older Adults
FDA staff reviewers said new data from Moderna's experimental flu vaccine appears to support its effectiveness in adults aged 65 and older.
Read Full Analysis
Adaptive Biotechnologies Plans Separation of Immune Medicine Platform
Adaptive Biotechnologies announced plans to separate its immune medicine business from the rest of the company, a move that could reshape its long-term...
Read Full Analysis
Baby Formula Maker Nara Issues Nationwide Recall After Infant Botulism Concerns
Infant formula manufacturer Nara announced a nationwide recall after concerns emerged that one of its products could be linked to infant botulism, a...
Read Full Analysis
Centene Offers Staff Buyouts After Obamacare Membership Losses
Health insurer Centene is offering buyouts to most of its employees after losing a significant number of members enrolled through Affordable Care Act...
Read Full Analysis
Ebola Risk at the 2026 World Cup Is Extremely Low, U.S. Experts Say
As preparations continue for the 2026 FIFA World Cup, public health experts are reassuring the public that the risk of Ebola spreading through the...
Read Full Analysis
Elicio Shares Tumble After Pancreatic Cancer Therapy Misses Mid-Stage Trial Goal
Shares of Elicio Therapeutics fell sharply after the company announced that its experimental pancreatic cancer treatment failed to achieve the primary...
Read Full Analysis
Mead Johnson Wins New Trial After Court Reverses $60 Million Premature Infant Formula Verdict
A court overturned a $60 million jury verdict against Mead Johnson and ordered a new trial in a closely watched lawsuit involving infant formula and...
Read Full Analysis
Amgen Orders Independent Review of Tavneos Data
Amgen hired an outside research firm to conduct an independent review of clinical data related to Tavneos. The move follows questions surrounding certain aspects of the drug's data and performance.
Read Full Analysis
CMS Proposes Rule for Future Medicare Drug Price Negotiations
The Centers for Medicare & Medicaid Services proposed new rules governing Medicare drug-price negotiations scheduled for 2029. The proposal outlines how future rounds of the federal drug-pricing program...
Read Full Analysis
Express Scripts Challenges Tennessee Prescription Drug Law
Express Scripts, the pharmacy-benefit manager owned by Cigna, filed a lawsuit seeking to block a Tennessee law that affects how prescription drugs are distributed and reimbursed. The company argues the law...
Read Full Analysis
FDA Approves Sanofi's Drug for Stage 3 Type 1 Diabetes in Children
The FDA approved Sanofi's treatment for children with Stage 3 Type 1 diabetes, expanding options for young patients living with the autoimmune disease. The approval marks an important step because Type 1...
Read Full Analysis
FDA Clears First Over-the-Counter Glucose Monitor for Children
The FDA cleared the first over-the-counter continuous glucose monitor that can be purchased for children without a prescription. The device allows families to monitor glucose levels more easily and may...
Read Full Analysis
Jazz Pharmaceuticals Lung Cancer Drug Misses Main Trial Goal
Jazz Pharmaceuticals reported that an experimental lung-cancer treatment failed to achieve the primary goal in a clinical trial. The result represents a setback for the company and raises questions about...
Read Full Analysis
Novartis Reports Promising Early Results for Rare Muscle Disease Drug
Novartis announced encouraging early-stage trial results for a treatment targeting a rare muscle disease. The company reported signs that the therapy may benefit patients, though larger studies will be...
Read Full Analysis
United States Commits Additional $50 Million to Ebola Response
The U.S. government announced another $50 million in funding to support efforts aimed at controlling the Ebola outbreak. The money will support surveillance, healthcare operations, response teams, and other...
Read Full Analysis
Takeda's AI-Designed Psoriasis Pill Outperforms Bristol Myers Drug in Study
Takeda reported that its experimental psoriasis pill, developed with the help of artificial intelligence, performed better than Bristol Myers Squibb's Sotyktu in a head-to-head clinical trial. The results suggest the...
Read Full Analysis
Camurus Hormone Disorder Drug Faces Another FDA Delay
Camurus said its hormone-disorder treatment is now unlikely to receive FDA approval until 2027 after encountering another regulatory setback. The company must address additional FDA concerns before the review process...
Read Full Analysis
FDA Grants Emergency Approval for Over-the-Counter Screwworm Treatment for Pets
The FDA granted emergency approval for an over-the-counter treatment designed to help combat screwworm infections in pets. The action comes as officials continue responding to growing concerns about screwworm cases...
Read Full Analysis
FDA Issues Import Alert for Drugs Manufactured at Dabur India Facility
The FDA issued an import alert covering drugs manufactured at a Dabur India facility after inspectors identified quality and compliance concerns. An import alert allows regulators to stop affected products from...
Read Full Analysis
GSK Rebuilds Cancer Pipeline With $11 Billion Nuvalent Deal
GSK agreed to acquire Nuvalent in a deal valued at approximately $11 billion, strengthening the company's oncology portfolio. The acquisition gives GSK access to promising cancer-drug candidates and expands its...
Read Full Analysis
Heart Drug Developer Kardigan Targets $1.4 Billion Valuation in U.S. IPO
Kardigan, a biotechnology company developing treatments for cardiovascular disease, filed plans for a U.S. initial public offering that could value the company at approximately $1.4 billion. The company is focused on...
Read Full Analysis
Novo Nordisk Investigates Cyber Incident and Possible Data Breach
Novo Nordisk disclosed that it was investigating a cyber incident that may have involved unauthorized access to company data. The pharmaceutical giant said it was working to determine what information may have been...
Read Full Analysis
PharmaSource Says It Did Not Know Dexcom Sensors Were Intended for Destruction
PharmaSource said it was unaware that Dexcom glucose sensors it purchased had been designated for destruction rather than resale. The dispute follows concerns that stolen or improperly distributed medical devices had...
Read Full Analysis
Rising Screwworm Cases Put Federal Preparedness Efforts to the Test
As additional screwworm cases are identified in the United States, federal agencies are being forced to put months of preparation and response planning into action. Officials are expanding monitoring, containment,...
Read Full Analysis
Some U.S. Employers Plan to Drop Coverage for GLP-1 Obesity Drugs
A growing number of U.S. employers are considering eliminating insurance coverage for obesity drugs such as Wegovy and Zepbound because of rapidly rising costs. These medications have become extremely popular and...
Read Full Analysis
Judge Rejects Nationwide Attempt to Block DOJ Transgender-Care Subpoenas
A federal judge rejected a broad request to block DOJ subpoenas seeking transgender-care records, keeping healthcare organizations exposed to case-by-case legal and compliance pressure.
Read Full Analysis
Novo Nordisk Battles South African Compounder Over Weight-Loss Drug Copies
Novo Nordisk is seeking to stop a South African compounding pharmacy from making and selling unauthorized semaglutide versions amid rising demand for GLP-1 weight-loss medicines.
Read Full Analysis
Older Drug Appears to Improve Blood Sugar Control in Type 1 Diabetes
Researchers reported that a low-cost older drug may improve blood sugar control in Type 1 diabetes by affecting immune-system pathways tied to the disease.
Read Full Analysis
Organon Wins FDA Approval to Expand Use of Arthritis Biosimilar
Organon received FDA approval to expand the use of its arthritis biosimilar TOFIDENCE, widening its clinical and commercial pathway in high-need settings.
Read Full Analysis
U.S. Doctor Released After Ebola Monitoring in Czech Republic
A U.S. doctor was released from monitoring in the Czech Republic after completing quarantine following possible Ebola exposure, highlighting international biosecurity coordination.
Read Full Analysis
ICE Detention Center in Texas Criticized Over Medical Care and Missing Records
A government watchdog report found serious medical-care failures, missing records, and oversight concerns at an ICE detention center in Texas.
Read Full Analysis
mRNA Cancer Vaccines Continue Advancing Despite Federal Funding Cuts
Researchers and biotechnology companies developing mRNA-based cancer vaccines say progress continues despite reductions in some U.S. government funding programs.
Read Full Analysis
NIH Appoints Acting Leader of Major Infectious Disease Institute
The U.S. National Institutes of Health appointed John Powers III as acting director of the National Institute of Allergy and Infectious Diseases (NIAID).
Read Full Analysis
Parabilis Medicines Increases IPO Target to $633 Million
Parabilis Medicines increased the size of its planned U.S. initial public offering and now aims to raise approximately $633 million. The expansion suggests stronger-than-expected investor demand for the biotechnology...
Read Full Analysis
Philips Says AI Is Improving Clinical Accuracy
The North America CEO of Philips Healthcare said artificial intelligence is helping clinicians improve diagnostic accuracy and make better healthcare decisions.
Read Full Analysis
Previously Shelved Alcohol Study Finds Independent Publication
A study examining alcohol's effects on health that was previously sidelined has now been published in an independent scientific journal. The research revisits long-standing questions about whether moderate alcohol...
Read Full Analysis
Samsung Invests $175 Million in Genomics Company Element Biosciences
Samsung Electronics invested $175 million in Element Biosciences as part of the company's latest Series E funding round. Element develops advanced DNA sequencing technologies used by researchers, healthcare...
Read Full Analysis
Survey Finds AI Saves Clinicians Time, But Most Lack Training
A new survey found that healthcare professionals using AI generally believe it saves time and improves efficiency. However, most respondents said they have received little formal training on how to use these tools...
Read Full Analysis
FDA Approves First New Sunscreen Ingredient in Decades
The FDA expanded sunscreen options by approving a new sunscreen ingredient, marking the first completely new active ingredient approved in the United States since the 1990s.
Read Full Analysis
ICE Detention Center in Texas Criticized Over Medical Care and Missing Records
A new government watchdog report from the Government Accountability Office (GAO) has uncovered severe systemic failures at ICE’s largest detention facility, Camp East Montana at Fort Bliss in Texas. The investigation...
Read Full Analysis
Health Experts Plan to Monitor World Cup Wastewater for Disease Outbreaks
Public health officials announced plans to monitor wastewater during the 2026 FIFA World Cup in the United States, Mexico, and Canada to detect potential disease outbreaks early.
Read Full Analysis
Johnson & Johnson to Acquire Firefly Bio for $1 Billion
Johnson & Johnson agreed to acquire Firefly Bio in a deal worth approximately $1 billion.
Read Full Analysis
Nineteen More Medical Schools Commit to Nutrition Training
The U.S. Department of Health and Human Services announced that 19 additional medical schools have committed to expanding nutrition education for future physicians.
Read Full Analysis
USDA Confirms Two Additional Screwworm Cases in the United States
The U.S. Department of Agriculture confirmed two additional cases of New World screwworm in the United States.
Read Full Analysis
Early Pregnancy Use of GLP-1 Drugs Should Not Cause Immediate Alarm, Study Suggests
Researchers reported findings suggesting that accidental use of GLP-1 drugs during early pregnancy may not pose the level of risk that some people feared.
Read Full Analysis
FDA Approves Pfizer's Bleeding Disorder Drug for Children
The FDA approved a bleeding-disorder treatment from Pfizer for use in children.
Read Full Analysis
Gavi Plans to Use U.S. Funding for Malaria Programs While Meeting New Conditions
Gavi, the international vaccine alliance, said it plans to continue using U.S. funding for malaria-related programs while also complying with new conditions.
Read Full Analysis
CDC Warns Current Ebola Outbreak Could Resemble the 2014 Crisis
The CDC warned that the ongoing Ebola outbreak in Central Africa could potentially reach a scale similar to the devastating 2014 West Africa outbreak if containment efforts fail.
Read Full Analysis
Johnson & Johnson Wins Trial Over Talc Cancer Claims
Johnson & Johnson won a lawsuit brought by three women who claimed the company's talc products caused their cancer.
Read Full Analysis
Judge Refers DOJ Lawyers for Possible Discipline in Transgender-Care Records Fight
A federal judge in Rhode Island, Mary McElroy, referred two Department of Justice lawyers for potential disciplinary review after finding they may have misrepresented facts during a legal battle over transgender-care records. The dispute centers on DOJ...
Read Full Analysis
Second Screwworm Parasite Case Confirmed in Texas
A second case of New World screwworm was confirmed in Texas, increasing concerns among animal-health officials and the cattle industry.
Read Full Analysis
Structure Therapeutics Says Experimental Obesity Pill Shows No Signs of Liver Injury
Structure Therapeutics reported new data showing that its experimental obesity pill did not show evidence of liver injury during testing.
Read Full Analysis
U.S. Experts Arrive in Kenya Despite Legal Challenges to Ebola Facility
American experts arrived in Kenya to continue work related to a planned Ebola quarantine facility despite ongoing court challenges and public protests.
Read Full Analysis
U.S. Provides Nearly $38 Million More for Ebola Response
The United States announced nearly $38 million in additional funding for Ebola response efforts, bringing total direct U.S. support to more than $200 million during the outbreak. The funding will support response activities in affected regions and help...
Read Full Analysis
U.S. Treatment Centers Say They Are Ready for Ebola Patients
Officials from the U.S. network of specialized treatment centers said they are prepared to handle Ebola patients if necessary, even as the government continues pursuing plans for a quarantine facility in Kenya. At least nine of the country's specialized...
Read Full Analysis
Abbott Must Face Lawsuit Over PediaSure Growth Claims
A federal judge ruled that Abbott Laboratories must face a proposed class-action lawsuit alleging that its PediaSure Grow & Gain drinks misled consumers into believing they were clinically proven to help children grow taller.
Read Full Analysis
LaserAway Explores Potential Sale
Ares-backed medical spa chain LaserAway is reportedly exploring a sale.
Read Full Analysis
New Federal Fraud Initiative Raises Risks for Healthcare Companies
Healthcare and life sciences companies are being warned that a new federal civil-rights and fraud enforcement initiative could increase legal exposure across the industry.
Read Full Analysis
Parabilis Medicines Seeks Up to $475 Million in U.S. IPO
Biotechnology company Parabilis Medicines filed plans for a U.S. initial public offering that could raise up to $475 million.
Read Full Analysis
Trump Administration Cuts Funding to Hawaii Medicaid Fraud Unit
The Trump administration ended federal funding for Hawaii's Medicaid fraud investigation unit after determining that it was not pursuing enough fraud cases.
Read Full Analysis
U.S. Senators Question Tobacco Industry Lobbying After FDA Policy Changes
Several U.S. senators questioned whether major tobacco companies influenced recent FDA policy changes involving nicotine and tobacco regulation.
Read Full Analysis
U.S. Supreme Court Backs Generic Drugmaker in Major Patent Case
The U.S. Supreme Court unanimously ruled in favor of generic drugmaker Hikma Pharmaceuticals in a patent dispute involving Amarin's heart drug Vascepa.
Read Full Analysis
Acting FDA Chief Meets Rare Disease Groups to Repair Relations
Acting FDA Commissioner Kyle Diamantas met with rare disease advocacy groups after months of tension between regulators, patients, and biotech companies focused on rare diseases.
Read Full Analysis
Alnylam and Inceptive Sign AI Drug Discovery Deal Worth Up to $2 Billion
Alnylam Pharmaceuticals signed a partnership worth up to $2 billion with Inceptive to use artificial intelligence in drug discovery.
Read Full Analysis
FDA Reviews AI Tool Designed to Predict Drug-Related Liver Damage
The FDA is evaluating a new artificial intelligence tool designed to predict whether an experimental drug could cause liver damage before it reaches patients.
Read Full Analysis
GLP-1 Drugs May Offer Benefits Across Multiple Types of Cancer
New research suggested that GLP-1 drugs, the same class of medicines used for diabetes and weight loss, may have beneficial effects across several different types of cancer.
Read Full Analysis
Judge Allows States' Lawsuit Challenging Transgender-Care Probes to Move Forward
A federal judge allowed a lawsuit filed by several U.S. states to continue against federal investigations into transgender healthcare providers.
Read Full Analysis
Judge Blocks Florida's Lawsuit Against Group Supporting Transgender Youth Care
A federal judge blocked Florida from pursuing part of its lawsuit against an organization that supports healthcare for transgender youth.
Read Full Analysis
Lilly Cuts Planned Germany Investment by Half
Eli Lilly and Company said it would reduce a previously announced $2.3 billion investment in Germany.
Read Full Analysis
Lilly Licenses Gene-Editing Technology for Kidney Disease Research
Eli Lilly and Company signed a licensing agreement with Ascidian Therapeutics to gain access to gene-editing technology that could be used to develop treatments for kidney diseases.
Read Full Analysis
Medline Receives Second FDA Warning in Two Months Over Quality Issues
The FDA issued another warning letter to Medline Industries, marking the second warning the company received within two months.
Read Full Analysis
Radiation-Emitting Implant Improves Outcomes After Brain Cancer Surgery
Researchers reported positive results from a radiation-emitting implant placed directly into the brain after surgery for aggressive brain tumors.
Read Full Analysis
Unconfirmed U.S. Screwworm Case Shakes Cattle Markets
Reports of a possible case of New World screwworm in the United States unsettled livestock markets and raised concerns among agricultural and animal health officials.
Read Full Analysis
U.S. Ebola Team Arrives in Kenya Despite Court Order and Protests
American experts arrived in Kenya to help establish a facility intended to monitor Americans exposed to Ebola, despite ongoing legal challenges and public protests.
Read Full Analysis
Abivax Shares Sink After Bowel Disease Drug Results
Abivax SA released important clinical trial results for a treatment targeting inflammatory bowel disease.
Read Full Analysis
CDC Warns About Risks of Getting Cosmetic Surgery Abroad
The CDC issued a warning about the growing number of Americans who travel overseas for cosmetic procedures and then return with serious health complications.
Read Full Analysis
Celcuity Shares Plunge After Breast Cancer Trial Results Disappoint
Celcuity Inc. released new data from a clinical trial involving an experimental breast cancer treatment. While the treatment showed some positive results, investors had been expecting stronger evidence that it would significantly improve patient outcomes.
Read Full Analysis
FDA Rejects Cingulate's ADHD Drug Application
The FDA declined to approve an ADHD medication developed by Cingulate and asked the company for additional information before it can make a final decision.
Read Full Analysis
FDA Wants to Speed Up Gene Therapy Development
The FDA proposed allowing gene therapy developers to rely more heavily on existing scientific knowledge instead of repeating studies that are already well understood.
Read Full Analysis
Fulcrum Scraps Sickle Cell Drug Program After FDA Cancer-Risk Concerns
Fulcrum Therapeutics stopped development of its lead sickle cell disease treatment after the FDA raised concerns about a potential cancer risk.
Read Full Analysis
Health Experts Oppose U.S. Plan to Treat Ebola-Exposed Americans Overseas
Some public health experts criticized a U.S. proposal that would involve monitoring or treating Americans exposed to Ebola outside the United States before they return home.
Read Full Analysis
Kenya Defends Planned U.S.-Backed Ebola Quarantine Facility
Kenya's president defended plans for a U.S.-supported Ebola quarantine facility after criticism from local communities and public protests.
Read Full Analysis
Praxis Epilepsy Drug Misses Main Goal in Clinical Trial
Praxis Precision Medicines announced that its experimental epilepsy treatment failed to achieve the primary goal in a mid-to-late-stage clinical trial.
Read Full Analysis
Travere Signs $1.14 Billion Kidney Disease Drug Deal
Travere Therapeutics signed a licensing agreement with Everest Medicines worth up to $1.14 billion for a kidney disease treatment.
Read Full Analysis
U.S. Issues New Guidance for Medicaid Work Requirements
Federal officials released guidance explaining how states can implement Medicaid work requirements.
Read Full Analysis
U.S. May Appoint a Dedicated Ebola Response Coordinator
Secretary of State Marco Rubio said the U.S. government is considering appointing a dedicated official to oversee the country's Ebola response.
Read Full Analysis
U.S. May Re-Engage With Global Vaccine Alliance Gavi
The United States signaled that it may strengthen cooperation with Gavi, an international organization that helps fund and distribute vaccines in lower-income countries.
Read Full Analysis
West Pharmaceutical Appoints New CEO
West Pharmaceutical Services appointed a new chief executive officer, bringing in a former executive from Thermo Fisher Scientific.
Read Full Analysis
Edgewise to Sell Muscle-Dystrophy Business to Servier for Up to $2.65 Billion
Edgewise Therapeutics agreed to sell its muscle-dystrophy business to Servier in a deal worth up to $2.65 billion.
Read Full Analysis
Haisco and Lilly Sign Collaboration and Licensing Deals
A unit of China's Haisco Pharmaceutical entered collaboration and licensing agreements with Eli Lilly and Company involving experimental medicines.
Read Full Analysis
Hundreds Protest Planned U.S. Ebola Quarantine Facility in Kenya
Hundreds of people protested plans for a U.S.-supported Ebola quarantine facility in Kenya that would have housed Americans potentially exposed to the virus before returning to the United States.
Read Full Analysis
Merck Discussing Use of COVID Antiviral Drug in Ebola Response
A senior executive at Merck & Co. said the company is discussing whether its COVID antiviral drug could be used as part of the response to the ongoing Ebola outbreak.
Read Full Analysis
Moderna Partners to Develop Vaccine for Bundibugyo Ebola Strain
Moderna partnered with a global health coalition to develop a vaccine targeting the Bundibugyo strain of Ebola, the strain responsible for the ongoing outbreak.
Read Full Analysis
U.S. Approves Oral Drug to Help Prevent COVID-19
The FDA approved an oral drug from Shionogi & Co. to help prevent COVID-19 infection.
Read Full Analysis
UnitedHealthcare to Remove Prior Authorization Requirements for Nearly Two-Thirds of Services
UnitedHealthcare announced it will eliminate prior authorization requirements for nearly two-thirds of medical services that previously required insurer approval before treatment.
Read Full Analysis
U.S. Court Overturns $452 Million Trade Secret Verdict Against Insulet
A U.S. appeals court overturned a $452 million verdict against Insulet Corporation in a trade-secret dispute involving insulin pump technology.
Read Full Analysis
U.S., Mexico and Canada Announce Ebola Travel Measures Ahead of World Cup
The United States, Mexico, and Canada announced coordinated Ebola-related travel measures ahead of the 2026 FIFA World Cup.
Read Full Analysis
WHO Chief Heads to Congo as Ebola Outbreak Strains Response
WHO Director-General Tedros Adhanom Ghebreyesus traveled to the Democratic Republic of Congo as the Ebola outbreak continued worsening and putting pressure on local healthcare systems.
Read Full Analysis
Bristol Myers Drug Delays Progression of Hard-to-Treat Multiple Myeloma
Bristol Myers Squibb reported that one of its experimental treatments delayed disease progression in patients with difficult-to-treat multiple myeloma, a type of blood cancer.
Read Full Analysis
FDA Advisers Weigh Composition of COVID Vaccines for 2026–2027
FDA vaccine advisers met to discuss which COVID-19 strain should be targeted in vaccines for the 2026–2027 season.
Read Full Analysis
FDA Approves MannKind’s Inhaled Insulin for Children
The FDA approved MannKind Corporation's inhaled insulin for children with diabetes.
Read Full Analysis
Johnson & Johnson Defeats Heart Pump Patent Claims
Johnson & Johnson successfully defended itself against patent claims involving heart-pump technology in a U.S. trial.
Read Full Analysis
Lilly’s Mounjaro Outperforms Other GLP-1 Drugs in Some Diabetes Patients
Mounjaro from Eli Lilly and Company showed stronger results than competing GLP-1 medicines in some patients with type 2 diabetes.
Read Full Analysis
Massachusetts Sues UnitedHealth Unit for Allegedly Defrauding Medicaid
Massachusetts sued a unit of UnitedHealth Group, alleging it improperly billed the state's Medicaid program and received payments it was not entitled to.
Read Full Analysis
Replimune Reaches Agreement With FDA to Resubmit Melanoma Drug Application
Replimune Group reached an agreement with the FDA on a path to resubmit its melanoma drug application after previous regulatory setbacks.
Read Full Analysis
Amazon Puts Amwell Co-Founder in Charge of Healthcare Unit
Amazon appointed an Amwell co-founder to lead its healthcare division after a longtime executive departed.
Read Full Analysis
Americans Are Dropping Out of Obamacare Plans
Many Americans are actively leaving Affordable Care Act (Obamacare) insurance plans, with a highly noticeable decline occurring in Kentucky. Shifting baseline operational costs and revised eligibility criteria are cited as the primary catalysts driving consumers away from these exchanges.
Read Full Analysis
California Sues 23andMe Over 2023 Data Breach
California filed a major lawsuit against 23andMe over its 2023 data breach, which exposed highly sensitive genetic and personal information belonging to millions of users.
Read Full Analysis
CVS Restores Coverage for Lilly’s Obesity Drug Zepbound
CVS Health officially restored insurance coverage for Zepbound, the hyper-growth obesity treatment developed by Eli Lilly and Company. The critical formulary decision significantly expands consumer access to one of the fastest-growing weight-loss medications on the commercial market.
Read Full Analysis
CVS, Walgreens and Walmart Defeat Florida Hospital Opioid Lawsuit
CVS Health, Walgreens Boots Alliance, and Walmart successfully defeated a high-stakes lawsuit brought by Florida hospitals regarding the national opioid crisis.
Read Full Analysis
FDA Advisers Vote in Favor of Updating COVID Vaccines for XFG Variant
An FDA advisory committee voted overwhelmingly in favor of recommending that COVID-19 vaccines for the 2026–27 season target the XFG variant, which had become the dominant strain in the U.S.
Read Full Analysis
FDA Advisers Weigh Composition of COVID Vaccines for 2026–2027
FDA vaccine advisers met to decide whether COVID-19 vaccines for the 2026–2027 season should be updated to target the XFG variant, which had become the dominant strain circulating in the United States.
Read Full Analysis
U.S. Court Overturns $452 Million Trade Secret Verdict Against Insulet
A U.S. appeals court overturned a $452 million verdict against Insulet Corporation involving alleged insulin pump trade-secret theft.
Read Full Analysis
U.S. HHS Finalizes Rule to Streamline “No Surprises Act” Disputes
The U.S. Department of Health and Human Services (HHS) finalized critical structural changes to simplify and accelerate the Independent Dispute Resolution (IDR) process under the No Surprises Act.
Read Full Analysis
U.S., Mexico and Canada Announce Ebola Travel Measures Ahead of World Cup
The United States, Mexico, and Canada announced coordinated Ebola-related travel measures ahead of the 2026 FIFA World Cup.
Read Full Analysis
WHO Chief Heads to Congo as Ebola Outbreak Strains Response
WHO Director-General Tedros Adhanom Ghebreyesus traveled to the Democratic Republic of Congo as the Ebola outbreak continued worsening and putting pressure on healthcare systems.
Read Full Analysis
Apogee Secures Up to $1.3 Billion From Blackstone to Advance Eczema Drug
Apogee Therapeutics secured up to $1.3 billion from Blackstone to help develop its eczema treatment.
Read Full Analysis
Blood Test Added to U.S. Colorectal Cancer Screening Options
A blood test was officially added as a recognized U.S. colorectal cancer screening option, significantly expanding medical alternatives to traditional colonoscopy-based screening protocols.
Read Full Analysis
Cardiovascular Drug Developer Kardigan Files for U.S. IPO
Biotech company Kardigan filed for a U.S. stock market listing to raise capital for the development of its specialized cardiovascular pipelines.
Read Full Analysis
Insulet Flags Dosing Defect in Some Omnipod Devices
Insulet Corporation warned about a dosing defect affecting certain Omnipod insulin delivery devices.
Read Full Analysis
Rubio Says U.S. Cannot Allow Any Ebola Cases to Enter Country
U.S. Secretary of State Marco Rubio stated that the United States cannot allow Ebola cases to cross its borders as outbreak concerns continue to escalate.
Read Full Analysis
U.S. Sets Up Quarantine Facility in Kenya for Americans Exposed to Ebola
The U.S. has planned a strategic quarantine facility in Kenya specifically for American citizens potentially exposed to Ebola before they return home.
Read Full Analysis
Veracyte Test Identifies Breast Cancer Patients Who Can Skip Chemotherapy
Veracyte announced that its genomic test successfully helped identify breast cancer patients who may safely avoid chemotherapy.
Read Full Analysis
Zuckerberg Philanthropic Venture Unveils AI “World Model” for Drug Discovery
A philanthropic initiative backed by Mark Zuckerberg unveiled an AI system designed to simulate biological processes and accelerate drug discovery.
Read Full Analysis
Alabama Warns Healthcare Providers Against Non-FDA-Approved Peptides
Alabama health officials issued a sharp warning to healthcare providers against prescribing or selling non-FDA-approved peptide products.
Read Full Analysis
Lilly to Buy Three Vaccine Developers for Nearly $4 Billion
Eli Lilly announced nearly $4 billion in acquisitions involving three vaccine developers, strengthening its infectious disease pipeline and global vaccine capabilities.
Read Full Analysis
Big Tobacco Comes Out on Top After FDA Shake-Up
FDA leadership and organizational changes may benefit tobacco and nicotine companies by slowing regulatory momentum around nicotine and vaping oversight.
Read Full Analysis
Dexcom Warns Patients as Stolen Glucose Sensors Hit the Market
Dexcom warned patients that stolen glucose sensors were being sold through unauthorized channels, raising concerns around device safety and supply chain security.
Read Full Analysis
FDA Advisers to Weigh Updating 2026–27 COVID Vaccines for XFG Variant
FDA advisers will consider whether 2026–27 COVID vaccines should be updated for the XFG variant, keeping vaccine strain selection and manufacturer readiness in focus.
Read Full Analysis
WHO Warns Ebola Outbreak Is Outpacing Response Efforts
WHO warned that the Ebola outbreak in the Democratic Republic of Congo is spreading faster than response efforts, raising urgent global health security concerns.
Read Full Analysis
U.S. Adds Atlanta-Area Airport for Ebola Screening
The CDC expanded Ebola screening measures by adding the Atlanta airport area as a designated entry point for travelers arriving from Ebola-affected countries.
Read Full Analysis
U.S. Extends Ebola Travel Ban to Green-Card Holders
The U.S. expanded Ebola-related travel restrictions to include lawful permanent residents (green-card holders) who had recently been in Ebola-affected countries.
Read Full Analysis
Early Childhood Screening for Type 1 Diabetes May Benefit Patients
Researchers reported that screening children early for Type 1 diabetes may help identify the disease before severe symptoms develop.
Read Full Analysis
FDA Approves Gilead Drug for Deadly Liver Infection
The FDA approved a new Gilead drug to treat a serious liver infection, creating a new treatment option for high-risk patients.
Read Full Analysis
U.S. HHS Launches AI Initiative to Detect Fraud and Waste in Health Programs
HHS launched an AI-powered initiative to detect fraud, waste, and misuse of federal healthcare funds across health programs and audit records.
Read Full Analysis
Minnesota Nonprofit Leader Sentenced to 41 Years in $250 Million Fraud Scheme
A Minnesota nonprofit leader was sentenced to 41 years in prison for a $250 million fraud scheme tied to federal child nutrition funds.
Read Full Analysis
Meta Settles First U.S. Case Over School Costs Linked to Youth Mental Health
Meta settled a U.S. case claiming social media contributed to youth mental health costs faced by schools, widening legal risk for digital platforms.
Read Full Analysis
Lilly Says Patients Lost 28% of Body Weight on Next-Generation Obesity Drug
Eli Lilly reported that patients lost an average of 28% of body weight on its next-generation obesity drug in a clinical trial.
Read Full Analysis
FDA to Hold Expert Committee Meeting on Moderna Flu Vaccine
The FDA scheduled an expert committee meeting to review Moderna’s experimental mRNA flu vaccine, signaling momentum in vaccine platform expansion.
Read Full Analysis
Families Consider Moving States to Preserve Access to Gender-Affirming Care
Families are considering moving states to preserve access to gender-affirming care as hospitals and policies shift across the U.S.
Read Full Analysis
Ebola Cases Rise; Returning Americans Must Enter Through Washington Dulles Airport
As Ebola cases rise, returning Americans from the Democratic Republic of Congo must enter through Washington Dulles for screening and monitoring.
Read Full Analysis
U.S. Senator Durbin Urges RFK Jr. Not to Ease Vape Rules
Senator Durbin urged Health Secretary Robert F. Kennedy Jr. not to weaken vape regulations, keeping youth nicotine addiction and public health risk in focus.
Read Full Analysis
U.S. Health Secretary Kennedy Fires Members of Key Preventive Health Panel
Health Secretary Kennedy removed members of a key preventive health panel, raising questions around screening guidance, public health recommendations, and policy influence.
Read Full Analysis
U.S. Doctor Exposed to Ebola to Be Hospitalized in Czech Republic
A U.S. doctor exposed to Ebola will be hospitalized in the Czech Republic for precautionary monitoring, showing continued global outbreak-response coordination.
Read Full Analysis
Pfizer’s Pneumococcal Vaccine Shows Strong Mid-Stage Trial Results
Pfizer reported strong mid-stage trial results for its pneumococcal vaccine, strengthening its vaccine pipeline and adult respiratory disease prevention strategy.
Read Full Analysis
Medtronic Plans $650 Million Acquisition of SPR Therapeutics
Medtronic plans to acquire SPR Therapeutics for about $650 million, expanding its position in non-opioid pain treatment and nerve stimulation devices.
Read Full Analysis
Court Allows Rhode Island Hospital to Release Transgender Care Records to Texas
A court allowed a Rhode Island hospital to release transgender care records to Texas investigators, highlighting legal pressure around patient privacy and interstate healthcare disputes.
Read Full Analysis
Common Asthma Drug May Improve Cancer Immunotherapy Performance
Researchers found that a common asthma drug may improve cancer immunotherapy performance, pointing to new opportunities in drug repurposing and combination therapy.
Read Full Analysis
Bristol Myers Using Anthropic’s Claude AI to Speed Drug Discovery
Bristol Myers Squibb is using Anthropic’s Claude AI to accelerate drug discovery workflows, showing how AI is moving deeper into pharmaceutical R&D.
Read Full Analysis
Healthcare AI Firm Commure Valued at $7 Billion After New Funding
Healthcare AI company Commure raised $70 million in new funding, pushing its valuation to about $7 billion.
Read Full Analysis
Nestlé and Danone Face Scrutiny Over Baby Formula Recalls
Nestlé and Danone faced scrutiny over baby formula recalls tied to contamination and safety concerns.
Read Full Analysis
Takeda Found Guilty of Delaying Cheaper Generic Drug Competition
A U.S. jury found that Takeda Pharmaceutical Company delayed cheaper generic versions of a constipation drug through anti-competitive behavior.
Read Full Analysis
Trump Says TrumpRx Will Carry 600 Generic Drugs
Trump announced that TrumpRx would expand to offer 600 generic drugs aimed at lowering medicine costs.
Read Full Analysis
Jury Finds Takeda Delayed Generic Constipation Drug Competition
A U.S. jury found that Takeda Pharmaceutical Company participated in an antitrust scheme that delayed cheaper generic versions of a constipation drug.
Read Full Analysis
Trump Plans Expansion of Discount Drug Pricing Program
The Trump administration planned to expand discount drug pricing efforts aimed at lowering medicine costs in the U.S.
Read Full Analysis
UnitedHealth Falls After Berkshire Hathaway Sells Stake
UnitedHealth Group shares fell after Berkshire Hathaway sold its stake in the company.
Read Full Analysis
U.S. Health Department Withdraws Vaccine Advisory Panel Charter
The U.S. Health Department withdrew the charter for a vaccine advisory panel involved in guiding vaccine recommendations.
Read Full Analysis
U.S. Moves to Curb Ebola Risk, Says Immediate Public Risk Is Low
The U.S. government announced new precautions to reduce Ebola risk after outbreaks in Africa, while saying the immediate risk to the American public remains low.
Read Full Analysis
U.S. Supreme Court Rejects Pharma Challenge to Drug Price Negotiation Law
The U.S. Supreme Court rejected a pharmaceutical industry challenge against a Biden-era Medicare drug pricing law.
Read Full Analysis
Adult Dies From Hantavirus in Colorado
Colorado health officials confirmed an adult died from hantavirus, a rare disease linked to rodent exposure.
Read Full Analysis
Boston Scientific Invests $1.5 Billion in Heart Valve Company Mirus
Boston Scientific invested $1.5 billion in Mirus with the option to eventually buy its heart valve business.
Read Full Analysis
CDC Says One American Tested Positive for Ebola
The U.S. CDC confirmed that one American tested positive for Ebola after exposure linked to the African outbreak.
Read Full Analysis
Elliott Builds Major Stake in Bio-Rad Laboratories
Activist investment firm Elliott Management built a major stake in Bio-Rad Laboratories, a company that makes lab tools and diagnostic equipment.
Read Full Analysis
Flawed Tests and Funeral Practices Allowed Ebola Spread Undetected
Reuters reported that testing failures and unsafe funeral practices may have allowed Ebola to spread undetected during the African outbreak.
Read Full Analysis
Acting CDC Chief Says White House Receiving Daily Hantavirus Updates
The acting CDC chief said the White House is receiving daily hantavirus updates, showing how outbreak monitoring and public health communication remain high-priority federal signals.
Read Full Analysis
Common ADHD Medicines May Help Treat Cancer-Related Fatigue
Common ADHD medicines may help treat cancer-related fatigue, pointing to new supportive-care opportunities for oncology patients and care teams.
Read Full Analysis
Deadline Passes for Supreme Court Extension on Abortion Pill Mail Access
A key deadline passed in the Supreme Court extension battle over abortion pill mail access, keeping reproductive healthcare policy and legal access in focus.
Read Full Analysis
FDA Drug Center Head Expected to Leave Agency
The expected departure of the FDA drug center head adds leadership uncertainty at a critical time for pharma regulation, approvals, and drug safety oversight.
Read Full Analysis
Hantavirus Outbreak Tests Post-COVID Public Health Communication
A hantavirus outbreak is testing post-COVID public health communication, highlighting the need for clear outbreak messaging and trust-building strategies.
Read Full Analysis
Texas Hospital to Launch Youth “Detransition” Clinic After State Investigation
A Texas hospital will launch a youth detransition clinic after a state investigation, reflecting growing legal scrutiny around gender-related healthcare services.
Read Full Analysis
U.S. CDC Monitoring Ebola Outbreak in Africa
The U.S. CDC is monitoring an Ebola outbreak in Africa, underscoring the global surveillance role of public health agencies and outbreak-response systems.
Read Full Analysis
U.S. Moves to End Job Protections for Hundreds of Health Department Workers
The U.S. moved to end job protections for hundreds of health department workers, raising questions about federal workforce stability and public health operations.
Read Full Analysis
WHO Warns Nicotine Pouches Could Increase Youth Addiction
WHO warned that nicotine pouches could increase youth addiction, adding regulatory pressure to fast-growing nicotine and consumer health products.
Read Full Analysis
CVS Unit Omnicare Wins Court Approval to Sell Genierx
Omnicare, a CVS Health unit, received court approval to divest its Genierx pharmacy business, continuing the trend of healthcare portfolio restructuring and long-term care divestiture.
Read Full Analysis
U.S. Cancer Clinics Rush to Access Experimental Pancreatic Cancer Drug
Cancer clinics across the U.S. are racing to secure access to a promising experimental pancreatic cancer drug, highlighting urgent unmet need in one of oncology's hardest-to-treat segments.
Read Full Analysis
U.S. Judge Blocks Justice Department Attempt to Restrict Rhode Island
A federal judge blocked the DOJ's effort to restrict Rhode Island's transgender healthcare policies, underscoring how legal rulings continue to shape the evolving landscape of gender-affirming care access.
Read Full Analysis
Easing Medical Costs Help Health Insurers But Bigger Risks Remain
Health insurers are seeing temporary relief as medical costs ease, but claims pressure, inflation, and market uncertainty continue to create bigger risks.
Read Full Analysis
Eli Lilly Launches Alzheimer’s Drug Donanemab in India
Eli Lilly launched Donanemab in India, expanding access to Alzheimer’s treatment and strengthening global neurology market momentum.
Read Full Analysis
KKR-Backed Ambulance Giant GMR Raises $478.7 Million in U.S. IPO
Emergency medical services provider GMR raised nearly $479 million through its U.S. IPO, highlighting investor interest in emergency infrastructure.
Read Full Analysis
U.S. Defers $1.3 Billion Medicaid Funds to California
The U.S. government deferred $1.3 billion in Medicaid funds to California, raising questions around policy disputes and healthcare funding stability.
Read Full Analysis
U.S. Halts Medicare Enrollment for New Home Healthcare and Hospice Providers
Medicare enrollments for some new home healthcare and hospice providers have been paused in high-risk areas to prevent fraud and suspicious billing.
Read Full Analysis
Google-Backed Isomorphic Raises $2.1 Billion for AI Drug Discovery
AI drug discovery company Isomorphic Labs raised $2.1 billion to expand its AI-driven pharmaceutical research platform.
Read Full Analysis
Hims & Hers Raises 2026 Revenue Forecast
Hims & Hers Health has raised its 2026 revenue forecast following robust demand for telehealth services, online prescriptions, and weight-loss treatments.
Read Full Analysis
Hims & Hers Shares Fall After Weight-Loss Strategy Hurts Quarterly Results
Hims & Hers Health shares dropped sharply after the company's aggressive focus on weight-loss treatments hurt quarterly performance.
Read Full Analysis
New York Hospital System Receives Grand Jury Subpoena in Transgender Care Probe
A major New York hospital system received a federal grand jury subpoena related to investigations into transgender healthcare for minors.
Read Full Analysis
OpenAI Faces Lawsuit Over Alleged Harmful Chatbot Advice
OpenAI is facing a lawsuit in California claiming ChatGPT allegedly gave advice that contributed to a person's death.
Read Full Analysis
Steris Forecasts Strong Profit on Procedure Demand
STERIS plc forecast stronger-than-expected profit growth, driven by demand for surgical and medical procedures.
Read Full Analysis
Prison Health Company YesCare Lost 80% Revenue After Malpractice Verdict
Prison healthcare company YesCare reportedly lost around 80% of its revenue after a major malpractice verdict damaged its business relationships.
Read Full Analysis
Hims & Hers Raises 2026 Revenue Forecast
Hims & Hers raises its 2026 revenue forecast as online healthcare subscriptions, weight-loss treatments, and telehealth demand accelerate.
Read Full Analysis
Lilly Halts India Obesity Awareness Campaign After Regulatory Scrutiny
Lilly pauses an India obesity awareness campaign after regulatory scrutiny, showing how GLP-1 growth is creating global marketing pressure.
Read Full Analysis
Amazon to Sell Ozempic Through U.S. Kiosks With Same-Day Delivery
Amazon expands GLP-1 access through U.S. kiosks and same-day delivery, showing how retail logistics are reshaping healthcare access.
Read Full Analysis
Entrada Duchenne Drug Improves Muscle Function in Early Trial
Entrada's early Duchenne data points to renewed momentum in rare disease drug development and muscle-function focused therapies.
Read Full Analysis
Italy's Angelini Pharma to Buy U.S. Catalyst Pharma in $4.1 Billion Deal
Angelini's planned Catalyst acquisition shows how specialized drug portfolios are becoming strategic assets in global pharma.
Read Full Analysis
State Attorneys General Increase Antitrust and Consumer Protection Enforcement
Rising state-level enforcement adds a new regulatory pressure layer for healthcare companies, payers, and life sciences businesses.
Read Full Analysis
Cencora Raises Annual Profit Forecast Despite Quarterly Miss
Cencora's raised forecast highlights how healthcare distribution profitability depends on operational discipline, even when revenue growth softens.
Read Full Analysis
CVS Health Raises 2026 Forecast After Improving Medical Cost Controls
CVS Health's stronger forecast shows how medical cost control is becoming central to payer margins and managed care performance.
Read Full Analysis
DaVita Lifts Annual Profit Forecast on Strong Dialysis Demand
DaVita's outlook reflects the stability of chronic kidney care demand and the durable economics of recurring healthcare services.
Read Full Analysis
Healthcare Affordability Becomes Top Concern for U.S. Voters
Healthcare affordability is becoming a dominant voter issue, shaping policy pressure, payer strategy, and consumer healthcare expectations.
Read Full Analysis
CVS to Drop Johnson & Johnson's Stelara From Key Drug Lists
CVS's Stelara formulary move shows how payer and PBM decisions can redirect market share toward lower-cost biosimilars.
Read Full Analysis
HIV Prevention Uptake Rises but Coverage Gaps Remain
Rising HIV prevention uptake shows progress, but insurance and coverage gaps continue to restrict broader preventive care adoption.
Read Full Analysis
Pfizer Beats Profit Estimates on Strong Eliquis Demand
Pfizer's performance shows how core drug demand continues to anchor pharma growth after the decline of pandemic-era revenue spikes.
Read Full Analysis
UnitedHealthcare Removes Prior Authorization for 30% of Services
UnitedHealthcare's move reduces prior authorization friction, showing how administrative access policies directly shape care delivery.
Read Full Analysis
U.S. Drug Pricing Deal Projected to Save $64.3 Billion
The projected drug-pricing savings show how federal pricing pressure may reshape pharma economics and reimbursement strategy.
Read Full Analysis
Viridian Therapeutics Eye Disease Drug Succeeds in Late-Stage Trial
Viridian's late-stage success strengthens its eye-disease pipeline and highlights how clinical milestones create biotech value.
Read Full Analysis
Weight-Loss Drug Boom Drives Surge in Protein Demand
GLP-1 adoption is creating downstream demand for protein products as patients focus on maintaining muscle during weight loss.
Read Full Analysis
Emergency Medical Services Provider GMR Files for U.S. IPO
GMR's IPO filing shows emergency medical infrastructure becoming an investable segment within the broader healthcare market.
Read Full Analysis
GLP-1 Weight-Loss Boom Drives Demand for Aesthetic Procedures
Rapid GLP-1 weight loss is creating demand for aesthetic procedures, expanding the commercial impact of obesity drugs beyond pharma.
Read Full Analysis
Mirum Pharmaceuticals Mid-Stage Liver Disease Drug Succeeds
Mirum's mid-stage result shows how clinical validation in rare liver disease can unlock meaningful biotech value.
Read Full Analysis
Odyssey Therapeutics Files for U.S. IPO
Odyssey's IPO plan signals renewed investor appetite for biotech listings and the funding cycles behind healthcare innovation.
Read Full Analysis
U.S. Health Secretary Pushes for Fast Policy Wins Ahead of Election
Fast-moving policy initiatives show how political timelines can influence healthcare priorities, pricing, and innovation pathways.
Read Full Analysis
U.S. Supreme Court Temporarily Restores Access to Abortion Pill via Telemedicine
The Supreme Court's temporary order highlights how legal rulings can reshape telemedicine access and healthcare delivery overnight.
Read Full Analysis
Universal Health Services Beats Estimates but Flags Pressure
UHS outperformed expectations, but continued labor, supply, and reimbursement pressure point to deeper provider-margin stress.
Read Full Analysis
Moderna Cuts Forecast Amid Declining COVID Vaccine Demand
Moderna's lowered outlook shows how pandemic-era demand is fading and why future growth depends on broader mRNA pipeline execution.
Read Full Analysis
Medicare Portal Data Breach Exposes Provider Social Security Numbers
A Medicare portal breach exposed sensitive provider data, highlighting healthcare cybersecurity as a core operational risk layer.
Read Full Analysis
Medicare Advantage Plans May Cut Extra Benefits in 2027
MA plans may reduce dental, vision, fitness, transport, and other supplemental benefits as cost and reimbursement pressure intensifies.
Read Full Analysis
CVS Health Beats Estimates as Medical Costs Stabilize
CVS results suggest medical cost trends are stabilizing, supporting payer margins and integrated care-delivery models.
Read Full Analysis
Amgen Weight-Loss Drug Shows Promising Early Results
Amgen's early obesity drug data signals a widening competitive field in one of healthcare's fastest-growing therapeutic markets.
Read Full Analysis
Merck Beats Sales Estimates on Strong Cancer Drug Demand
Merck's stronger sales reflect sustained demand for oncology assets and the continued revenue power of blockbuster cancer therapies.
Read Full Analysis
FDA Proposes Restricting Compounded Weight-Loss Drugs
FDA's proposal could limit compounded GLP-1 alternatives, strengthening branded market control while raising access questions.
Read Full Analysis
Eli Lilly Raises Forecast on Continued GLP-1 Demand
Strong demand for diabetes and weight-loss therapies pushes Lilly's outlook higher, reinforcing GLP-1 as a core pharma growth pillar.
Read Full Analysis
Cigna Raises Profit Forecast and Exits ACA Marketplace
Cigna's decision signals a strategic shift toward more predictable payer revenue pools and away from ACA marketplace volatility.
Read Full Analysis
Cardinal Health Raises Profit Forecast on Specialty Drug Demand
Specialty drug demand strengthens Cardinal Health's outlook, showing how high-value therapies drive growth across the supply chain.
Read Full Analysis
Baxter Beats Estimates on Strong Demand for Medical Products
Baxter's results show continued resilience in hospital products, therapy solutions, and essential medical supply demand.
Read Full Analysis
Eli Lilly Investors Focus on Obesity Pill Launch Performance
Investors are watching early prescription data as Lilly's obesity pill launch shifts from market hype to measurable commercial performance.
Read Full Analysis
CMS Extends Deadlines for Medicaid Drug Pricing Model
CMS gives states and drugmakers more time to prepare for a Medicaid pricing model aimed at lowering prescription drug costs.
Read Full Analysis
U.S. Seeks New Nominees for Key Preventive Health Panel
HHS seeks new members for the U.S. Preventive Services Task Force, exposing the importance of policy infrastructure in preventive care.
Read Full Analysis
Regeneron Pharmaceuticals Beats Estimates on Strong Drug Demand
Demand for Dupixent and Libtayo supports Regeneron's performance, reinforcing the strength of chronic and specialty care markets.
Read Full Analysis
Pfizer Cancer Drug Succeeds in Late-Stage Trial
Pfizer's blood cancer therapy met its primary late-stage goal, strengthening its oncology pipeline and approval prospects.
Read Full Analysis
Humana Beats Estimates but Signals Medicare Pressure
Humana's earnings strength comes with continued concern around Medicare funding, reimbursement, and payer economics.
Read Full Analysis
GE HealthCare Cuts Profit Forecast Due to Inflation
Rising chip, freight, and energy costs pressure GE HealthCare's margins despite demand for imaging and diagnostic equipment.
Read Full Analysis
Boston Scientific Procedure Outperforms Drugs for Heart Rhythm Disorder
A minimally invasive Boston Scientific procedure shows stronger potential than medication for atrial fibrillation treatment.
Read Full Analysis
AbbVie Beats Estimates as New Drugs Offset Humira Decline
AbbVie's newer therapies help offset Humira erosion, showing why portfolio replacement strategy defines pharma resilience.
Read Full Analysis
Centene Raises Profit Forecast on Improving Cost Control
Centene's stronger Q1 performance signals how cost control, utilization management, and payer margin discipline are reshaping healthcare economics.
Read Full Analysis
Eli Lilly Signs $2.25B Genetic Medicine AI Partnership
Lilly's partnership with Profluent shows how AI-designed biology is becoming a core infrastructure layer for future pharma pipelines.
Read Full Analysis
FDA Leadership Transition Update
FDA leadership uncertainty highlights how regulatory direction, institutional priorities, and approval confidence can shape healthcare innovation.
Read Full Analysis
Incyte Beats Estimates on Strong Cancer Drug Demand
Incyte's results show oncology remains one of healthcare's most resilient revenue engines, supported by strong drug demand and pipeline investment.
Read Full Analysis
Pfizer Secures Deals to Delay Generic Competition
Pfizer's exclusivity strategy shows how patent timelines and legal agreements can protect revenue as much as product innovation.
Read Full Analysis
Purdue Pharma Sentencing Advances Opioid Settlement
Purdue's sentencing advances a major opioid settlement and shows how legal accountability can reshape healthcare companies and public trust.
Read Full Analysis
Zimmer Biomet Signals Cautious Outlook Amid Operational Changes
Zimmer Biomet's cautious outlook shows how internal execution, sales force structure, and provider demand determine MedTech value capture.
Read Full Analysis
Intellia Gene-Editing Therapy Shows Strong Late-Stage Results
Intellia's lonvo-z™ achieved an 87% reduction in swelling attacks in Phase 3, marking the first global late-stage success for an in vivo CRISPR therapy.
Read Full Analysis
South Carolina Measles Outbreak Ends
Officials declared the nation's largest measles outbreak in 35 years over after 997 infections in Spartanburg County — exposing system-level gaps in preventive care coverage.
Read Full Analysis
Medtronic Reports Cyberattack on IT Systems
ShinyHunters claimed to have exfiltrated 9M+ PII records from Medtronic's corporate IT environment, underscoring cybersecurity as a core operational risk in healthcare.
Read Full Analysis
U.S. FDA Moves to Fast-Track Psychedelic Drugs
A new executive order directs the FDA to accelerate review for psychedelic-based treatments, creating rapid access pathways for breakthrough therapies targeting PTSD and addiction.
Read Full Analysis
CureVac Sues Moderna Over COVID-19 Vaccine Patents
CureVac filed a lawsuit alleging Moderna's Spikevax infringed on eight mRNA stabilization patents. This legal battle could force an industry-wide re-evaluation of mRNA licensing models.
Read Full Analysis
Type 2 Diabetes Procedure Helps Sustain Weight Loss After GLP-1 Drugs
A minimally invasive metabolic procedure signals a potential shift from continuous drug dependence toward durable obesity and diabetes treatment pathways.
Read Full Analysis
HCA Healthcare Beats Profit Estimates but Signals Volume Pressure
HCA's earnings strength masks deeper stress around admissions, surgical volumes, payer mix, and reimbursement quality.
Read Full Analysis
Eli Lilly Obesity Pill Sees Early Prescription Uptake
Early prescription momentum shows strong market appetite for oral obesity treatment and non-injectable GLP-1 alternatives.
Read Full Analysis
Health Insurers Move to Standardize Prior Authorization
Major U.S. insurers are standardizing prior authorization workflows, signaling a push to reduce care delays and administrative friction.
Read Full Analysis
White House–Regeneron Drug Pricing Deal
As part of the "most-favored-nation" initiative, Regeneron agrees to lower Medicaid prices and offer cholesterol drug Praluent for $225 on TrumpRx.
Read Full Analysis
U.S. Reclassifies Marijuana as Less Dangerous Drug
The DOJ moves to loosen federal restrictions on certain marijuana products, a historic shift that could unlock new treatment categories and clinical research.
Read Full Analysis
Regeneron Gene Therapy Approved by FDA
The FDA approves a landmark gene therapy for rare genetic deafness, signaling the transition of gene therapy from niche experimental stages to mainstream clinical use.
Read Full Analysis
Medicare's New RAPID Pathway: Closing the Coverage Gap
CMS and FDA launch a new initiative to slash the "valley of death" for medical devices, reducing the gap between approval and reimbursement to just 60–90 days.
Read Full Analysis
Merck Deal Interest: A Keytruda Ecosystem Expansion Signal
Merck targets Inhibrx Biosciences in a potential $8B deal, accelerating its strategy to bracket Keytruda before its 2028 patent cliff.
Read Full Analysis
Actuate Therapeutics Success: An Early-Stage Oncology Signal
Positive Phase 2 data for elraglusib in pancreatic cancer demonstrates how early trial signals shape future investment and M&A potential.
Read Full Analysis
Amneal Pharma Acquisition: A Massive Bet on Biosimilars
Amneal acquires Kashiv BioSciences for $1.1B, positioning itself to capitalize on a $300B wave of global biologic loss-of-exclusivity.
Read Full Analysis
Boston Scientific Cuts Forecast: A Signal of Device Market Pressure
Revised 2026 profit forecasts reflect cooling procedural demand and tight hospital capital spending, signaling new constraints for the MedTech sector.
Read Full Analysis
Elevance Health Raises Profit Forecast: A Margin Recovery Signal
Elevance beats Q1 expectations and raises guidance, shifting focus from raw enrollment growth to AI-driven efficiency and ruthless cost discipline.
Read Full Analysis
Medicare Obesity Drug Coverage Delay: A Payer Friction Signal
CMS delays the BALANCE Model pilot until 2027, highlighting the massive policy hurdles and payer friction facing blockbuster GLP-1 therapies.
Read Full Analysis
Hims & Hers Expands into Menopause Care Amid Patch Shortage
Hims & Hers enters menopause care with personalized treatment options as estradiol patch shortages create demand for alternative access models.
Read Full Analysis
CDC Publication Block: A New Era of Scientific Communication
A blocked CDC publication signals rising policy control over scientific communication, with implications for trust, transparency, and market adoption.
Read Full Analysis
UnitedHealth Group Signals Stabilization After Turbulent Period
UnitedHealth reported better-than-expected quarterly earnings and raised its full-year profit forecast, with medical costs coming in lower than expected.
Read Full Analysis
Diagnostics Demand Signals Continued Healthcare Utilization
Quest Diagnostics reported strong Q1 2026 results with revenue reaching $2.9 billion, raising its full-year forecast.
Read Full Analysis
Vaccine Guidance Disruption Creates Uncertainty in Preventive Care
A court ruling has disrupted processes guiding COVID-19 and essential vaccine recommendations, creating uncertainty for insurers and pharma.
Read Full Analysis
Cancer Drug Development Hits Setback in Late-Stage Trial
A combination cancer therapy from Merck and Eisai failed to improve survival outcomes in a late-stage kidney cancer trial.
Read Full Analysis
Bioprocessing Strength Signals Continued Investment in Drug Development
Danaher's Q1 results beat expectations as bioprocessing equipment demand signaled renewed momentum in drug development investment.
Read Full Analysis
The Medicaid Provider Revalidation Push: A System-Level Shift
The U.S. government is increasing pressure on states to revalidate high-risk Medicaid providers, with compliance and funding implications.
Read Full Analysis
Weight-Loss Drugs Are Quietly Reshaping the Cannabis Market
GLP-1 drugs are changing consumer cannabis behavior, forcing the industry to rethink appetite, experience, and product positioning.
Read Full Analysis
Psychedelics Are Moving Into Mainstream U.S. Healthcare
Regulators are being pushed to accelerate approvals for psychedelic-based treatments for depression, PTSD, and addiction.
Read Full Analysis